Literature DB >> 17045202

Searching for leukemia stem cells--not yet the end of the road?

Craig T Jordan1.   

Abstract

Defining the characteristics of leukemia stem cells is critical in order to better understand both the genesis of leukemic disease and strategies by which such cells may be eradicated. In this issue of Cancer Cell, Somervaille and Cleary describe studies in which the properties of malignant stem cells are elucidated in a mouse model of leukemia induced by expression of the MLL-AF9 translocation. Biological features of leukemia stem cells in this system challenge previous thinking in several ways and suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17045202     DOI： 10.1016/j.ccr.2006.09.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements.

Authors:  Richard Francis; Christine Richardson
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

Review 2.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Authors:  Carolina Schinke; Orsolya Giricz; Weijuan Li; Aditi Shastri; Shanisha Gordon; Laura Barreyro; Laura Barreryo; Tushar Bhagat; Sanchari Bhattacharyya; Nandini Ramachandra; Matthias Bartenstein; Andrea Pellagatti; Jacqueline Boultwood; Amittha Wickrema; Yiting Yu; Britta Will; Sheng Wei; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

Review 4.  Endometrial regeneration and endometrial stem/progenitor cells.

Authors:  Caroline E Gargett; Hong P T Nguyen; Louie Ye
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

5.  Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Wen-Juei Jeng; Ming-Che Yu; Hsin-Hua Tsai; Fang-Yu Chang; Jui-Chih Su
Journal:  Oncol Lett       Date:  2012-09-24       Impact factor: 2.967

6.  Etoposide-initiated MLL rearrangements detected at high frequency in human primitive hematopoietic stem cells with in vitro and in vivo long-term repopulating potential.

Authors:  Jolanta Libura; Maureen Ward; Joanna Solecka; Christine Richardson
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

7.  The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell.

Authors:  Dov Zipori
Journal:  Cancer Microenviron       Date:  2010-02-05

8.  Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors.

Authors:  E J Dettman; S J Simko; B Ayanga; B L Carofino; J F Margolin; H C Morse; M J Justice
Journal:  Oncogene       Date:  2011-02-21       Impact factor: 9.867

Review 9.  Sesquiterpenoid lactones as potential anti-cancer agents: an update on molecular mechanisms and recent studies.

Authors:  Praveen Dhyani; Priyanka Sati; Eshita Sharma; Dharam Chand Attri; Amit Bahukhandi; Bekzat Tynybekov; Agnieszka Szopa; Javad Sharifi-Rad; Daniela Calina; Hafiz A R Suleria; William C Cho
Journal:  Cancer Cell Int       Date:  2022-10-07       Impact factor: 6.429

10.  The sesquiterpene lactone dehydroleucodine triggers senescence and apoptosis in association with accumulation of DNA damage markers.

Authors:  Valeria V Costantino; Sabrina F Mansilla; Juliana Speroni; Celina Amaya; Darío Cuello-Carrión; Daniel R Ciocca; Horacio A Priestap; Manuel A Barbieri; Vanesa Gottifredi; Luis A Lopez
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.